PharmaCyte Biotech (PMCB) Other Accumulated Expenses (2012 - 2023)
PharmaCyte Biotech (PMCB) posted quarterly Other Accumulated Expenses of $287310.0 for Q3 2023, down 23.82% year-over-year from $377155.0 in Q3 2022, and little changed quarter-over-quarter from $287310.0 in Q2 2023.
PharmaCyte Biotech (PMCB) Other Accumulated Expenses (2012 - 2023) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Other Accumulated Expenses for 4 consecutive years, with $287310.0 the latest figure, recorded in Q3 2023.
- In Q3 2023, Other Accumulated Expenses fell 23.82% year-over-year to $287310.0; the TTM figure through Jul 2023 stood at $287310.0 (down 23.82% YoY), while the FY2023 annual figure was $287310.0, down 23.82% from the prior year.
- Other Accumulated Expenses steadied at $287310.0 in Q3 2023 per PMCB's latest filing, from $287310.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $467000.0 in Q1 2022 and bottomed at $287310.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2023 | 287,310.00 |
| Apr 30, 2023 | 287,310.00 |
| Jan 31, 2023 | 287,310.00 |
| Oct 31, 2022 | 377,155.00 |
| Jul 31, 2022 | 377,155.00 |
| Apr 30, 2022 | 377,155.00 |
| Jan 31, 2022 | 467,000.00 |
| Apr 30, 2013 | 2.34 Mn |
| Jan 31, 2013 | 2.30 Mn |
| Oct 31, 2012 | 2.26 Mn |
| Jul 31, 2012 | 2.23 Mn |